Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01267240 · OUTCOME

Survival

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer · Source last updated 2017-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 1 year

What was measured

Overall survival is defined as the length of time from start of treatment to death from any cause. Estimated using the Kaplan-Meier method.

Analysis population: 16 patients of the 25 were eligible for response assessment.

Groups in this outcome

Arm I (Capecitabine, Vorinostat)

Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Vorinostat: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Capecitabine, Vorinostat)16

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I (Capecitabine, Vorinostat)10.8Not reported5NANot reached
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Not reached
        group Id
        OG000
        lower Limit
        5
        upper Limit
        NA
        value
        10.8
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
description
Overall survival is defined as the length of time from start of treatment to death from any cause. Estimated using the Kaplan-Meier method.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Vorinostat: Given PO
    id
    OG000
    title
    Arm I (Capecitabine, Vorinostat)
param Type
MEDIAN
population Description
16 patients of the 25 were eligible for response assessment.
reporting Status
POSTED
time Frame
Up to 1 year
title
Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice